Brief: Hutchmed (China) Announces NMPA Conditional Approval For Atled (Fantegratinib) In China
28/08/2026 01:38
BRIEF-Hutchmed (China) Announces NMPA Conditional Approval For Atled (Fantegratinib) In China Aug 28 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
ANNOUNCES NMPA CONDITIONAL APPROVAL FOR ATLED (FANTEGRATINIB) IN CHINA
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation